Page 12 - Safety Will News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Written by Food & Drug Administration Following a thorough safety review, including two meetings of the CDC’s Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume. The pause was recommended after reports of six cases of a rare and severe type of blood clot in individuals following administration of the Janssen COVID-19 Vaccine. During the pause, medical and scientific teams at the FDA and CDC examined available data to assess the risk of thrombosis involving the cerebral venous sinuses, or CVST (large blood vessels in the brain), and other sites in the body (including but not limited to the large blood vessels of the abdomen and the veins of the legs) along with thrombocytopenia, or low blood platelet counts. The

United statesJohnson janssenJanet woodcockRochellep walenskyUs centers for diseaseUs department of healthHuman servicesDrug administrationAdvisory committee on immunization practicesImmunization practicesDisease controlFact sheetHealthcare providers administering vaccineVaccination providersAdvisory committeeSafety technical